Literature DB >> 20308526

Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI.

Basak E Dogan1, Ana Maria Gonzalez-Angulo, Michael Gilcrease, Mark J Dryden, Wei Tse Yang.   

Abstract

OBJECTIVE: We retrospectively reviewed imaging findings for 44 patients with triple receptor-negative breast carcinomas on mammography, sonography, and MRI to determine the imaging characteristics of triple receptor-negative cancers that may improve diagnosis at the time of presentation.
CONCLUSION: Despite their large size at presentation, triple receptor-negative cancers may be occult on mammography or sonography and frequently have benign or indeterminate features. MRI identified all triple receptor-negative cancers and showed features that had a high positive predictive value for malignancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308526     DOI: 10.2214/AJR.09.2355

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  43 in total

1.  Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.

Authors:  Ji Xiong; Wenli Tan; Jianbo Wen; Jiawei Pan; Yin Wang; Jun Zhang; Daoying Geng
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

Review 2.  Imaging Surveillance After Primary Breast Cancer Treatment.

Authors:  Diana L Lam; Nehmat Houssami; Janie M Lee
Journal:  AJR Am J Roentgenol       Date:  2017-01-11       Impact factor: 3.959

3.  Factors Associated with Preoperative Magnetic Resonance Imaging Use among Medicare Beneficiaries with Nonmetastatic Breast Cancer.

Authors:  Louise M Henderson; Julie Weiss; Rebecca A Hubbard; Cristina O'Donoghue; Wendy B DeMartini; Diana S M Buist; Karla Kerlikowske; Martha Goodrich; Beth Virnig; Anna N A Tosteson; Constance D Lehman; Tracy Onega
Journal:  Breast J       Date:  2015-10-28       Impact factor: 2.431

4.  Mammographic and clinicopathological features of triple-negative breast cancer.

Authors:  B Gao; H Zhang; S-D Zhang; X-Y Cheng; S-M Zheng; Y-H Sun; D-W Zhang; Y Jiang; J-W Tian
Journal:  Br J Radiol       Date:  2014-04-15       Impact factor: 3.039

5.  Triple receptor-negative breast cancer: imaging and clinical characteristics.

Authors:  Kristin M Krizmanich-Conniff; Chintana Paramagul; Stephanie K Patterson; Mark A Helvie; Marilyn A Roubidoux; Jamie D Myles; Kiting Jiang; Michael Sabel
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

6.  Role of MRI in the staging of breast cancer patients: does histological type and molecular subtype matter?

Authors:  Almir G V Bitencourt; Nara P Pereira; Luciana K L França; Caroline B Silva; Jociana Paludo; Hugo L S Paiva; Luciana Graziano; Camila S Guatelli; Juliana A Souza; Elvira F Marques
Journal:  Br J Radiol       Date:  2015-09-16       Impact factor: 3.039

7.  Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.

Authors:  Claire M B Holloway; Li Jiang; Marlo Whitehead; Jennifer M Racz; Patti A Groome
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-16       Impact factor: 4.553

8.  Invasive ductal carcinoma of the breast in a 14-year-old girl.

Authors:  Joo Yeon Kim; Yun Ju Kim; Sung Hun Kim; Bong Joo Kang; Byung Joo Song
Journal:  Pediatr Radiol       Date:  2014-07-06

9.  Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer.

Authors:  Jung Min Chang; In Ae Park; Su Hyun Lee; Won Hwa Kim; Min Sun Bae; Hye Ryoung Koo; Ann Yi; Seung Ja Kim; Nariya Cho; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2013-05-15       Impact factor: 5.315

10.  Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Authors:  Marjan S Bolouri; Sjoerd G Elias; Dorota J Wisner; Spencer C Behr; Randall A Hawkins; Sachiko A Suzuki; Krysta S Banfield; Bonnie N Joe; Nola M Hylton
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.